Aerie pharmaceuticals receives marketing authorisation of roclanda® 50 micrograms/ml + 200 micrograms/ml eye drops, solution (latanoprost + netarsudil) in great britain

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that roclanda® 50 micrograms/ml + 200 micrograms/ml eye drops, solution (latanoprost + netarsudil) (“roclanda®”) has received marketing authorisation from the medicines and healthca
AERI Ratings Summary
AERI Quant Ranking